King Wealth Management Group’s Theravance Biopharma TBPH Stock Holding History

King Wealth Management Group’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-45,000	Closed	-$408K	–	164
2022 Q2	$408K	Sell	45,000 -77,000	-63%	-$710K	0.1%	94
2022 Q1	$1.17M	Buy	122,000 +109,000	+838%	+$1.07M	0.23%	58
2021 Q4	$144K	Hold	13,000	–	–	0.03%	170
2021 Q3	$96K	Sell	13,000 -10,000	-43%	-$112K	0.02%	168
2021 Q2	$334K	Hold	23,000	–	–	0.07%	131
2021 Q1	$469K	Hold	23,000	–	–	0.11%	98
2020 Q4	$409K	Hold	23,000	–	–	0.1%	108
2020 Q3	$340K	Hold	23,000	–	–	0.09%	111
2020 Q2	$483K	Buy	23,000 +8,200	+55%	+$211K	0.14%	82
2020 Q1	$342K	Sell	14,800 -7,700	-34%	-$193K	0.15%	85
2019 Q4	$583K	Buy	22,500 +5,000	+29%	+$97.2K	0.15%	62
2019 Q3	$341K	Sell	17,500 -7,000	-29%	-$141K	0.1%	90
2019 Q2	$400K	Buy	24,500 +7,500	+44%	+$152K	0.12%	81
2019 Q1	$385K	Buy	+17,000	New	+$431K	0.12%	81

Other funds holding TBPH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

King Wealth Management Group's TBPH Position: Q3 2022 in Review

King Wealth Management Group sold out of Theravance Biopharma (TBPH) in Q3 2022, closing a stake of 45,000 shares — an estimated $408K sold.

King Wealth Management Group first reported a position in TBPH in Q1 2019 and held it in 14 quarters. The position peaked at $1.17M in Q1 2022. 123 funds tracked by Wall St. Rank hold TBPH as of Q3 2022.

King Wealth Management Group reported no remaining Theravance Biopharma position as of Q3 2022 after selling out during the quarter.
King Wealth Management Group sold 45,000 Theravance Biopharma shares in Q3 2022, an estimated $408K.
King Wealth Management Group first reported a position in Theravance Biopharma in Q1 2019 and held it in 14 quarters.
King Wealth Management Group's Theravance Biopharma position peaked at $1.17M in Q1 2022.
123 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2022.

Based on King Wealth Management Group's 13F filing for Q3 2022, filed 10 Nov 2022.